BCMA is preferentially expressed on plasma cells and other mature B cells in blood 5. These cells originate ... chimeric antigen receptor (CAR) T cells have the longest history of clinical ...
The following is a summary of “BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma,” published in ...
CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...
A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...
Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR ... as well as a risk for secondary blood cancers in line with an FDA review of the safety of the entire CAR-T class earlier this year.
Bristol-Myers Squibb’s anti-BCMA CAR-T therapy ide-cel is in pole position to reach the market, but could face tough competition from a rival Johnson & Johnson drug, according to data reported ...
Schematic illustration explaining the working principle of BCMA-CD19 bispecific CAR T cells used in current study. CD19 is the pan B cell marker but not expressed in long-lived plasma cells and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback